APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-23p19 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IL-23p19 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025183 pages

Choose your research edition.

Industry ResearchIL-23p19 Inhibitors Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-23p19 Inhibitors Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal IL-23p19 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-23p19 Inhibitors Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-23p19 Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global IL-23p19 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IL-23p19 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-23p19 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-23p19 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IL-23p19 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IL-23p19 Inhibitors include Innovent Biologics (Suzhou) Co. Ltd., Johnson & Johnson, Merck Sharp & Dohme Corp., Eli Lilly and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-23p19 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-23p19 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-23p19 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-23p19 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-23p19 Inhibitors Segment by Company

Innovent Biologics (Suzhou) Co. Ltd.

Johnson & Johnson

Merck Sharp & Dohme Corp.

Eli Lilly

AbbVie

IL-23p19 Inhibitors Segment by Type

100mg/mL

75mg/mL

IL-23p19 Inhibitors Segment by Application

Hospital

Clinic

Others

IL-23p19 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23p19 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-23p19 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23p19 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-23p19 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IL-23p19 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IL-23p19 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IL-23p19 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IL-23p19 Inhibitors Industry Trends Table 2. IL-23p19 Inhibitors Industry Drivers Table 3. IL-23p19 Inhibitors Industry Opportunities and Challenges Table 4. IL-23p19 Inhibitors Industry Restraints Table 5. Global IL-23p19 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IL-23p19 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IL-23p19 Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global IL-23p19 Inhibitors Sales Market Share by Manufacturers Table 9. Global IL-23p19 Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IL-23p19 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IL-23p19 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IL-23p19 Inhibitors Manufacturers, Product Type & Application Table 13. Global IL-23p19 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-23p19 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 100mg/mL Table 17. Major Manufacturers of 75mg/mL Table 18. Global IL-23p19 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global IL-23p19 Inhibitors Sales by Type (2021-2026) & (K Units) Table 20. Global IL-23p19 Inhibitors Sales by Type (2027-2032) & (K Units) Table 21. Global IL-23p19 Inhibitors Sales Market Share by Type (2021-2026) Table 22. Global IL-23p19 Inhibitors Sales Market Share by Type (2027-2032) Table 23. Global IL-23p19 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global IL-23p19 Inhibitors Revenue by Type (2021-2026) & (K Units) Table 25. Global IL-23p19 Inhibitors Revenue by Type (2027-2032) & (K Units) Table 26. Global IL-23p19 Inhibitors Revenue Market Share by Type (2021-2026) Table 27. Global IL-23p19 Inhibitors Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global IL-23p19 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global IL-23p19 Inhibitors Sales by Application (2021-2026) & (K Units) Table 33. Global IL-23p19 Inhibitors Sales by Application (2027-2032) & (K Units) Table 34. Global IL-23p19 Inhibitors Sales Market Share by Application (2021-2026) Table 35. Global IL-23p19 Inhibitors Sales Market Share by Application (2027-2032) Table 36. Global IL-23p19 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global IL-23p19 Inhibitors Revenue by Application (2021-2026) & (K Units) Table 38. Global IL-23p19 Inhibitors Revenue by Application (2027-2032) & (K Units) Table 39. Global IL-23p19 Inhibitors Revenue Market Share by Application (2021-2026) Table 40. Global IL-23p19 Inhibitors Revenue Market Share by Application (2027-2032) Table 41. Global IL-23p19 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global IL-23p19 Inhibitors Sales by Region (2021-2026) & (K Units) Table 43. Global IL-23p19 Inhibitors Sales Market Share by Region (2021-2026) Table 44. Global IL-23p19 Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global IL-23p19 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 46. North America IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America IL-23p19 Inhibitors Sales by Country (2021-2026) & (K Units) Table 48. North America IL-23p19 Inhibitors Sales by Country (2027-2032) & (K Units) Table 49. Europe IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe IL-23p19 Inhibitors Sales by Country (2021-2026) & (K Units) Table 51. Europe IL-23p19 Inhibitors Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific IL-23p19 Inhibitors Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific IL-23p19 Inhibitors Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa IL-23p19 Inhibitors Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa IL-23p19 Inhibitors Sales by Country (2027-2032) & (K Units) Table 58. Global IL-23p19 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global IL-23p19 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 60. Global IL-23p19 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 61. Global IL-23p19 Inhibitors Revenue Market Share by Region (2021-2026) Table 62. Global IL-23p19 Inhibitors Revenue Market Share by Region (2027-2032) Table 63. Innovent Biologics (Suzhou) Co. Ltd. Company Information Table 64. Innovent Biologics (Suzhou) Co. Ltd. Business Overview Table 65. Innovent Biologics (Suzhou) Co. Ltd. IL-23p19 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Innovent Biologics (Suzhou) Co. Ltd. IL-23p19 Inhibitors Product Portfolio Table 67. Innovent Biologics (Suzhou) Co. Ltd. Recent Development Table 68. Johnson & Johnson Company Information Table 69. Johnson & Johnson Business Overview Table 70. Johnson & Johnson IL-23p19 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Johnson & Johnson IL-23p19 Inhibitors Product Portfolio Table 72. Johnson & Johnson Recent Development Table 73. Merck Sharp & Dohme Corp. Company Information Table 74. Merck Sharp & Dohme Corp. Business Overview Table 75. Merck Sharp & Dohme Corp. IL-23p19 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck Sharp & Dohme Corp. IL-23p19 Inhibitors Product Portfolio Table 77. Merck Sharp & Dohme Corp. Recent Development Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly IL-23p19 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Eli Lilly IL-23p19 Inhibitors Product Portfolio Table 82. Eli Lilly Recent Development Table 83. AbbVie Company Information Table 84. AbbVie Business Overview Table 85. AbbVie IL-23p19 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. AbbVie IL-23p19 Inhibitors Product Portfolio Table 87. AbbVie Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. IL-23p19 Inhibitors Distributors List Table 91. IL-23p19 Inhibitors Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. IL-23p19 Inhibitors Product Image Figure 2. Global IL-23p19 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-23p19 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global IL-23p19 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global IL-23p19 Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IL-23p19 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 100mg/mL Image Figure 9. 75mg/mL Image Figure 10. Global IL-23p19 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global IL-23p19 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global IL-23p19 Inhibitors Sales Market Share by Type (2021-2032) Figure 13. Global IL-23p19 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global IL-23p19 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global IL-23p19 Inhibitors Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global IL-23p19 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global IL-23p19 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global IL-23p19 Inhibitors Sales Market Share by Application (2021-2032) Figure 22. Global IL-23p19 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global IL-23p19 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global IL-23p19 Inhibitors Revenue Market Share by Application (2021-2032) Figure 25. North America IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America IL-23p19 Inhibitors Sales Market Share by Country (2021-2032) Figure 27. U.S. IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe IL-23p19 Inhibitors Sales Market Share by Country (2021-2032) Figure 32. Germany IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific IL-23p19 Inhibitors Sales Market Share by Country (2021-2032) Figure 39. China IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa IL-23p19 Inhibitors Sales Market Share by Country (2021-2032) Figure 47. Brazil IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile IL-23p19 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global IL-23p19 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global IL-23p19 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America IL-23p19 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 58. North America IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe IL-23p19 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. Europe IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific IL-23p19 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa IL-23p19 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. IL-23p19 Inhibitors Value Chain Figure 66. Manufacturing Cost Structure Figure 67. IL-23p19 Inhibitors Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg/mL
  • 75mg/mL
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Innovent Biologics (Suzhou) Co. Ltd.
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.
  • Eli Lilly
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IL-23p19 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IL-23p19 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IL-23p19 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IL-23p19 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IL-23p19 Inhibitors Market Dynamics
  1. 2.1 IL-23p19 Inhibitors Industry Trends
  2. 2.2 IL-23p19 Inhibitors Industry Drivers
  3. 2.3 IL-23p19 Inhibitors Industry Opportunities and Challenges
  4. 2.4 IL-23p19 Inhibitors Industry Restraints
3 IL-23p19 Inhibitors Market by Manufacturers
  1. 3.1 Global IL-23p19 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IL-23p19 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global IL-23p19 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IL-23p19 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IL-23p19 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IL-23p19 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global IL-23p19 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IL-23p19 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IL-23p19 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IL-23p19 Inhibitors Tier 1, Tier 2, and Tier 3
4 IL-23p19 Inhibitors Market by Type
  1. 4.1 IL-23p19 Inhibitors Type Introduction
  2. 4.1.1 100mg/mL
  3. 4.1.2 75mg/mL
  4. 4.2 Global IL-23p19 Inhibitors Sales by Type
  5. 4.2.1 Global IL-23p19 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global IL-23p19 Inhibitors Sales by Type (2021-2032)
  7. 4.2.3 Global IL-23p19 Inhibitors Sales Market Share by Type (2021-2032)
  8. 4.3 Global IL-23p19 Inhibitors Revenue by Type
  9. 4.3.1 Global IL-23p19 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global IL-23p19 Inhibitors Revenue by Type (2021-2032)
  11. 4.3.3 Global IL-23p19 Inhibitors Revenue Market Share by Type (2021-2032)
5 IL-23p19 Inhibitors Market by Application
  1. 5.1 IL-23p19 Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global IL-23p19 Inhibitors Sales by Application
  6. 5.2.1 Global IL-23p19 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-23p19 Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global IL-23p19 Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global IL-23p19 Inhibitors Revenue by Application
  10. 5.3.1 Global IL-23p19 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IL-23p19 Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global IL-23p19 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global IL-23p19 Inhibitors Sales by Region
  1. 6.1 Global IL-23p19 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-23p19 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global IL-23p19 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global IL-23p19 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IL-23p19 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IL-23p19 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IL-23p19 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IL-23p19 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IL-23p19 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IL-23p19 Inhibitors Revenue by Region
  1. 7.1 Global IL-23p19 Inhibitors Revenue by Region
  2. 7.1.1 Global IL-23p19 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IL-23p19 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global IL-23p19 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global IL-23p19 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IL-23p19 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IL-23p19 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IL-23p19 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IL-23p19 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IL-23p19 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Biologics (Suzhou) Co. Ltd.
  2. 8.1.1 Innovent Biologics (Suzhou) Co. Ltd. Company Information
  3. 8.1.2 Innovent Biologics (Suzhou) Co. Ltd. Business Overview
  4. 8.1.3 Innovent Biologics (Suzhou) Co. Ltd. IL-23p19 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Biologics (Suzhou) Co. Ltd. IL-23p19 Inhibitors Product Portfolio
  6. 8.1.5 Innovent Biologics (Suzhou) Co. Ltd. Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson IL-23p19 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson IL-23p19 Inhibitors Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck Sharp & Dohme Corp.
  14. 8.3.1 Merck Sharp & Dohme Corp. Company Information
  15. 8.3.2 Merck Sharp & Dohme Corp. Business Overview
  16. 8.3.3 Merck Sharp & Dohme Corp. IL-23p19 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Sharp & Dohme Corp. IL-23p19 Inhibitors Product Portfolio
  18. 8.3.5 Merck Sharp & Dohme Corp. Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly IL-23p19 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly IL-23p19 Inhibitors Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie IL-23p19 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie IL-23p19 Inhibitors Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-23p19 Inhibitors Value Chain Analysis
  2. 9.1.1 IL-23p19 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-23p19 Inhibitors Production Mode & Process
  6. 9.2 IL-23p19 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-23p19 Inhibitors Distributors
  9. 9.2.3 IL-23p19 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst